Evolution of the Average Target: Veradigm Inc.

Evolution of the Average Target - Veradigm Inc.

Evolution of the Target Price: Veradigm Inc.

Evolution of the Target Price - Veradigm Inc.

Changes in Analyst Recommendations: Veradigm Inc.

b371c.hDwOO2f4mc7wGaZgb3tutYtyoGvvSgQllwm07ZQ-Z0A.4GlcSgHI6rugc_Q4JygY_sBH1lOjIT1S4kfDotZGJQjUb2lwBpvymohjkg~686e5b25e55b4eb78071ec12fecbccad
19/03/24 Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15 MT
19/01/24 RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating MT
03/01/24 Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target MT
11/12/23 Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating MT
06/07/23 Argus Research Downgrades Allscripts Healthcare Solutions to Hold From Buy MT
30/06/23 Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $18 From $21, Maintains Buy Rating MT
12/04/23 Stephens Initiates Allscripts Healthcare Solutions at Equalweight With $13 Price Target MT
01/02/23 Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $18.50 From $17 MT
18/11/22 JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating MT
09/11/22 Goldman Sachs Upgrades Allscripts Healthcare Solutions to Buy From Neutral, Adjusts Price Target to $23 From $22 MT
07/11/22 Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $21 From $20, Maintains Buy Rating MT
06/10/22 Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $26, Maintains Buy Rating MT
16/09/22 KeyBanc Initiates Coverage on Allscripts Healthcare Solutions With Sector Weight Rating MT
12/07/22 Goldman Sachs Starts Allscripts Healthcare Solutions at Neutral With $21 Price Target MT
10/06/22 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $19, Maintains Neutral Rating MT
18/03/22 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $22 From $19, Maintains Neutral Rating MT
04/03/22 Deutsche Bank Lifts Allscripts Healthcare Solutions to Buy From Hold, Price Target to $26 From $20 MT
03/03/22 SVB Leerink Adjusts Allscripts Healthcare Solutions' Price Target to $24 from $22, Keeps Outperform Rating MT
25/01/22 SVB Leerink Upgrades Allscripts Healthcare Solutions to Outperform from Market Perform, Adjusts Price Target to $22 from $19 MT
25/01/22 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Neutral Rating MT
23/11/21 Deutsche Bank Adjusts Allscripts Healthcare Solutions PT to $20 From $18, Maintains Hold Rating MT
08/11/21 Canaccord Genuity Adjusts Price Target on Allscripts Healthcare Solutions to $21 From $18, Keeps Buy Rating MT
06/08/21 Allscripts Healthcare : RBC Lifts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Outperform Rating MT
20/05/21 Allscripts Healthcare : Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $15, Maintains Hold Rating MT
02/03/21 Allscripts Healthcare : Argus Downgrades Allscripts Healthcare Solutions to Hold From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - +60%
+2%
+8.65%
+13.77%
+38.01%
+13.87%
+17.94%
-0.11%
+3.62%
+5.3%
Average +16.31%
Weighted average by Cap. +9.68%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.000USD
Average target price
8.000USD
Spread / Average Target
+60.00%
High Price Target
8.000USD
Spread / Highest target
+60.00%
Low Price Target
8.000USD
Spread / Lowest Target
+60.00%

Analyst Consensus Detail

Analyst consensus - Veradigm Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Veradigm Inc.
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Veradigm Inc.
  1. Stock Market
  2. Stocks
  3. MDRX Stock
  4. Consensus Veradigm Inc.